http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Equal contribution (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
콜라겐 유도 관절염 모델에서 동반된 치주염 유발시 EGCG가 치주염 치료에 미치는 효과에 관한 연구
조인우(In-Woo Cho),임성준(Seong-Jun Yim),신현승(Hyun-Seung Shin),박정철(Jung-Chul Park),Equal contribution 대한치과의사협회 2016 대한치과의사협회지 Vol.54 No.4
The aim of this study was to evaluate the effect of Epigallocatechin-3-Gallate (EGCG) on the alveolar bone metabolism in a collagen-induced arthritis (CIA) model in mice to enhance the understanding of rheumatoid arthritis (RA)-associated alveolar bone loss. Following the induction of CIA in animals (mice, n=16), mandibles were retrieved for micro-computed tomography (micro-CT) and isolation of alveolar bone cells (ABCs). In vitro osteogenic potentials of ABCs were evaluated and the mRNA expression of downstream effector genes was assessed. CIA was successfully induced in all animals, and micro-CT data showed that alveolar bone loss was significantly increased in the CIA group while the treatment of EGCG prevented the alveolar bone resorption. Osteogenesis by ABCs was significantly increased in the CIA+EGCG group in vitro. The analysis of mRNA expressions showed that osteoclastogenesis-associated genes were increased in CIA group while bone protecting genes were upregulated in EGCG treated group. The results demonstrate that EGCG downregulated the alveolar bone resorption in a CIA model in mice, and upregulation of bone protecting genes appear to be involved. Further studies are warranted.
-
( Keumbit Hwang ),( Wonseok Kang ),( Dong Hyun Sinn ),( Geum-youn Gwak ),( Yong-han Paik ),( Moon Seok Choi ),( Joon Hyeok Lee ),( Kwang Cheol Koh ),( Seung Woon Paik ),( Equally Contributed ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Daclatasvir in combination with asunaprevir (DCV/ASV) therapy has recently been introduced to Korea for treatment of genotype 1b chronic hepatitis C virus (HCV) infection. To date, the efficacy and safety of DCV/ASV has not been systematically investigated in a real-life clinical setting in Korea. We aimed to assess the efficacy and safety of DCVASV therapy in a real-life cohort of Korean patients with genotype 1b chronic HCV infection. Methods: Between July 2015 and April 2016, a total of 156 patients with genotype 1b chronic HCV infection were prospectively enrolled and underwent screening for the presence of NS5A resistance- associated variants (RAVs) in Samsung Medical Center, Seoul, Korea. Patients without NS5A RAVs were treated with DCV/ASV for 24 weeks. The primary endpoint was end of treatment response (ETR). Safety evaluations included adverse events. Results: The incidence of NS5A RAVs was 16.6% (L31M/F/V, 6.4%; Y93H, 10.2%). Overall, 42 patients (treatment-naive, 18; treatment- experienced, 24) had completed the treatment course. The median age was 65.4 years, and the majority of patients were female (66.6%). Eighteen (42.8%) patients had cirrhosis. ETR was achieved in 40 (95.2%) patients. ETR was comparable between the following subgroup of patients: treatment-naive (17/18, 94.4%) vs. treatment- experienced (23/24, 95.8%); non-cirrhotic (23/24, 95.8%) vs. cirrhotic (17/18, 94.4%); baseline HCV RNA levels <800,000 IU/ml (14/14, 100%) vs. ≥800,000 IU/mL (26/28, 92.8%). On-treatment virologic response showed undetectable HCV RNA in 38 (95%), 40 (97.5%) and 34 (94.4%) patients at week 4, 8 and 12, respectively. There was 1 serious adverse event leading to treatment discontinuation. The most common adverse events were headache, pruritus and fatigue. Conclusions: DCV/ASV therapy provided high ETR rates in both treatment- naive and treatment-experienced genotype 1b chronic HCV-infected patients without NS5A RAVs in Korea. Treatment was generally well-tolerated regardless of cirrhosis status.
DBpia
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
